Heart failure & cardiomyopathies
A novel monoclonal antibody targeting aggregated transthyretin facilitates its removal and functional recovery in an experimental model
Authors' conclusion
We developed a proprietary antibody targeting aggregated TTR that exhibits beneficial effects in a novel experimental wtATTR model and also possesses a potential diagnostic utility.
Study context
- Population
- Experimental model of wild-type ATTR (wtATTR) cardiac amyloidosis; sera and cardiac plaques of wtATTR patients
Main finding
As reported in the abstract
- IgG1 monoclonal antibody against aggregated TTR immunoprecipitated the protein in wtATTR patients' sera and robustly stained patients' cardiac plaques
- Antibody facilitated aggregated-TTR uptake by various myeloid cells and protected cardiomyocytes from TTR-inducible toxicity
- In vivo wtATTR model: antibody enhanced disappearance of pyrophosphate signals (rapid amyloid deposit removal and degradation) and improved echocardiographic measures of cardiac performance
- Antibody-based capture ELISA: higher aggregated TTR in sera of wtATTR amyloidosis patients vs control patients with HF
Original publication
A novel monoclonal antibody targeting aggregated transthyretin facilitates its removal and functional recovery in an experimental model. Eur Heart J. Published 22 December 2019. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →